北米のデング熱治療市場レポート–産業動向と2028年までの予測

北米のデング熱治療市場

Market Size in USD Billion

CAGR : 23.90 %

予測期間	2021 –2028
市場規模（基準年）	USD 71.42 Million
Market Size (Forecast Year)	USD 387.13 Million
CAGR	23.90 %
主要市場プレーヤー	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

>北米のデング熱治療市場、株別（DENV-1、DENV-2、DENV-3、DENV-4、その他）、感染経路（蚊から人への感染および母子感染）、タイプ別（薬物療法、支持療法、予防接種、その他）、重症度（単純および重症）、投与経路（経口および非経口）、購入方法（処方薬および市販薬（OTC））、エンドユーザー（病院、専門クリニック、在宅医療、その他）、流通チャネル（病院薬局、小売薬局、オンライン薬局、その他）、国別（米国、カナダ、メキシコ）業界動向および2028年までの予測

市場分析と洞察:北米のデング熱治療市場

デング熱治療市場は、2021年から2028年の予測期間に市場成長を遂げると予想されています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に23.9%のCAGRで成長し、2028年には7,142万米ドルから3億8,713万米ドルに達すると分析しています。市場関係者による戦略的取り組みとデング熱治療のための集団ワクチン接種プログラムの出現が、デング熱治療市場の主要な推進力となると考えられます。

デング熱は蚊が媒介するウイルス性疾患で、近年WHO（世界保健機関）の管轄地域全体で急速に広がっています。デング熱ウイルスは主にネッタイシマカ属の雌の蚊によって媒介され、程度は低いもののヒトスジシマカによっても媒介されます。これらの媒介蚊によって媒介される疾患は、チクングニア熱、黄熱病、ジカウイルスです。デング熱は熱帯地方で流行しており、降水量、気温、相対湿度、および地域によってリスクが異なる計画外の急速な都市化によって引き起こされます。

制御された措置にもかかわらず、デング熱の発生率が世界的に増加し、局所的な発生頻度が増加し、ネッタイシマカが繁殖する可能性があることから、デング熱治療のための治療オプションの消費が増加し、デング熱治療市場の推進力となることが予想されます。デング熱治療のコストは上記のとおり高く、多臓器不全などのデング熱に関連する合併症が増えると、治療の総コストが上昇し、感染者がデング熱治療の適切な治療法を避けることになり、デング熱治療市場の抑制要因となる可能性があります。デング熱は、従来は血清学的検査によって診断できますが、現在では技術のアップグレードにより、ウイルス検出のためのさまざまな進行中および開発された方法があり、デング熱治療市場に機会を生み出します。デング熱は、解熱剤や一部の抗生物質などの非特異的な薬物を伴うベクター媒介疾患ですが、世界中のさまざまな政府機関が講じる予防措置とイニシアチブは、デング熱治療市場にとって課題となることが予想されます。

The dengue treatment market report provides details of market share, new developments, and impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Dengue Treatment Market Scope and Market Size

The dengue treatment market is segmented on the basis of strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

On the basis of strains, the dengue treatment market is segmented into DENV-1, DENV-2, DENV-3, DENV-4, others. In 2021, DENV-2 segment is dominating the market as this strain is high in prevalence which results in higher infection cases of dengue fever. Although dengue can be caused by other strains too but the most dominant high clinical complication is seen in DENV-2.
On the basis of transmission, the dengue treatment market is segmented into mosquito-to-human transmission and mother-to-child transmission. In 2021, mosquito-to-human transmission segment is dominating in the market as the mosquitoes are the primary vector for the transmission of dengue for the different strains of the virus. When a mosquito bites an infected person it gets infected too and gets the virus in blood, and when a he again bite some other person the virus get transmitted to that person. This is the reason that mosquito-to-human transmission is dominating the market.
On the basis of type, the dengue treatment market is segmented into medication, supportive care, vaccination and others. In 2021, medication segment is dominating in the market as variety of drugs used for treating dengue are being used for the management of dengue fever from the very long time.
On the basis of severity, the dengue treatment market is segmented into uncomplicated and severe. In 2021, uncomplicated segment is dominating in the market the conversion rate of uncomplicated dengue to severe dengue is less than 5% which is the most important reason that the uncomplicated segment is dominating the dengue treatment market.
On the basis of route of administration, the dengue treatment market is segmented into oral and parenteral. In 2021, oral segment is dominating in the market as most of the drug that are taken to treat the symptoms of dengue are taken oral for pain management and fever management.
On the basis of mode of purchase, the dengue treatment market is segmented into prescription and over the counter (OTC). In 2021, prescription segment is dominating in the market as the medication and the supportive care is prescribed by the doctor after the confirmation the patient is infected by the dengue virus and the treatment options consist of antibiotics and other medication which are generally not available as prescribed medication only.
On the basis of end user, the dengue treatment market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating in the market as the symptoms of dengue can be managed at home using medications such as pain relief and fever management drugs after the diagnosis.
On the basis of distribution channel, the dengue treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the market as after proper diagnosis of dengue most of the prescriptions by patients are filled in retail pharmacies during the total duration of the treatment cycle of the infection.

Dengue Treatment Market Country Level Analysis

The dengue treatment market is analysed and market size information is provided by the country, strains, transmission, type, severity, route of administration, mode of purchase, end user and distribution channel as referenced above.

The countries covered in the dengue treatment market report are the U.S., Canada and Mexico.

The U.S. is expected to dominate in the North America dengue treatment market due to growing focus on increasing R&D activities in pharma and biotech sector and increase outsourcing services.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Necessity of Dengue Treatment in Urban Areas and the Strategic Intiatives by Market Players are is Creating New Opportunities for Players in the Dengue Treatment Market

The dengue treatment market also provides you with detailed market analysis for every country growth in particular industry with dengue treatment sales, impact of advancement in the dengue treatment and changes in regulatory scenarios with their support for the dengue treatment market. The data is available for historic period 2010 to 2019.

競争環境とデング熱治療市場シェア分析

デング熱治療市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータポイントは、デング熱治療市場に関連する会社の焦点にのみ関連しています。

デング熱治療薬を提供している主な企業としては、Aurobindo Pharma、Perrigo Company plc、Pfizer Inc.、Sun Pharmaceutical Industries Ltd.、Dr. Reddy's Laboratories Ltd.、Fresenius Kabi USA (Fresenius SE & Co. KGaA の子会社)、Baxter、Vitric Inc.、Hikma Pharmaceuticals PLC、Teva Pharmaceuticals USA, Inc. (Teva Pharmaceutical Industries Ltd. の子会社)、GlaxoSmithKline plc、Takeda Pharmaceutical Company Limited、Sanofi、EMERGEX VACCINES などがあります。DBMR のアナリストは、競争上の強みを理解しており、各競合他社の競合分析を個別に提供しています。

市場プレーヤーによるコラボレーション、合弁事業、その他の戦略により、デング熱治療市場における企業市場が強化され、組織にとってもデング熱治療市場への提供を改善するメリットがもたらされます。

SKU-59790

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

画像をクリックすると拡大します

インタラクティブなデータ分析ダッシュボード
成長の可能性が高い機会のための企業分析ダッシュボード
カスタマイズとクエリのためのリサーチアナリストアクセス
インタラクティブなダッシュボードによる競合分析
最新ニュース、更新情報、トレンド分析
包括的な競合追跡のためのベンチマーク分析のパワーを活用

デモのリクエスト

表のリスト

LIST OF TABLES

TABLE 1 NORTH AMERICA DENGUE TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION

TABLE 3 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 16 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 19 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 21 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 22 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION

TABLE 27 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION

TABLE 29 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION

TABLE 32 NORTH AMERICA OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION

TABLE 33 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 35 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 36 NORTH AMERICA SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 37 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 38 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 41 NORTH AMERICA ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 42 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 43 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICADENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 58 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 59 MEXICO DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 60 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 MEXICO MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 MEXICO ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 MEXICO OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 MEXICO VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 66 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 67 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 68 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 69 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 70 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 71 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 72 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 73 U.S. DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 74 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 U.S. MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 U.S. ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 U.S. OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 U.S. VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 80 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 U.S. ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 82 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 83 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 84 U.S. DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 85 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 86 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 87 CANADA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 88 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 CANADA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 CANADA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 CANADA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 CANADA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 94 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 95 CANADA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 98 CANADA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

図表一覧